This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chastagner, P. Articles by Duprez, A. Search for Related Content PubMed PubMed Citation Articles by Chastagner, P. Articles by Duprez, A.

In Vivo Potentiation of Radiation Response by Topotecan in Human Rhabdomyosarcoma Xenografted into Nude Mice

Pediatric Oncology Department [P. C.] and Experimental Microsurgery Laboratory [A. D.], CHU Nancy, Nancy; Oncology Research Laboratory [J. L. M., M. B-H.] and Radiation Therapy Department [C. M., S. H.], Centre A. Vautrin, Nancy; and Pharmacotoxicology and Pharmacogenetic Department, Institut G. Roussy, Villejuif [G.V.], France

The lack of new highly efficacious drugs for cancer treatment promotes the search for innovative therapeutic modalities. The authors reported the results leading to the definition of parameters needed to demonstrate a possible radiopotentiation by topotecan (TPT) on two representative human rhabdomyosarcomas (RMSs) xenografted into nude mice. Experimental studies of radiopotentiation with different doses of topotecan showed that concomitant association of topotecan and RT for 5 consecutive days provided a synergistic therapeutic effect. Response rates were statistically higher with the radiochemotherapeutic combination (P < 0.001). Efficacy enhancement factors of this combination compared with the sum of the antitumoral activity of these treatments separately administrated were 1.54 and 1.60, respectively, on both rhabdomyosarcomas. Moreover, the efficiency of the combination of radiotherapy at the dose of 20 Gy with topotecan (12.5 mg/kg) was not statistically different from that of radiotherapy at the dose of 40 Gy. According to microscopy results, the analyses performed at different periods after topotecan treatment alone, radiotherapy alone, and their combination seemed to show that tumoral repopulation by malignant cells is as fast as the dose of radiotherapy and/or topotecan is low. Furthermore, lesions observed with the dose of 40 Gy were similar to those obtained with the association of topotecan at the dose of 12.5 mg/kg and radiotherapy at the dose of 20 Gy. In conclusion, all clinical and pathological results are consistent with a radiopotentiation effect of topotecan on the two xenografted human rhabdomyosarcomas and are currently leading to the design of clinical studies.

This article has been cited by other articles:

				Z. Wang, T. Cook, S. Alber, K. Liu, I. Kovesdi, S. K. Watkins, Y. Vodovotz, T. R. Billiar, and D. Blumberg Adenoviral Gene Transfer of the Human Inducible Nitric Oxide Synthase Gene Enhances the Radiation Response of Human Colorectal Cancer Associated with Alterations in Tumor Vascularity Cancer Res., February 15, 2004; 64(4): 1386 - 1395. [Abstract] [Full Text] [PDF]